When was ReViral founded?

ReViral was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is ReViral located?

ReViral is headquartered in London, United Kingdom. It is registered at 2530 Meridian Parkway 2nd Floor Durham North Carolina.

How many employees does ReViral have?

As of Sep 30, 2026, the latest employee count at ReViral is 5.

Is ReViral a funded company?

ReViral is a funded company, having raised a total of $176M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 02, 2014.

When was the latest funding round of ReViral?

ReViral's latest funding was a $***** Series C round on Aug 25, 2020, with participation from 7 investors.

What is the annual revenue of ReViral?

Annual revenue of ReViral is between £1M and £10M as on Apr 30, 2021

Where does ReViral rank among its competitors?

ReViral ranks 15th amongst 65 active competitors, of which 17 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Aer Therapeutics, which secured $3M in Aug, 2026.

Who are the top competitors of ReViral?

ReViral's top competitors include Precigen, Pulmocide and Genome & Company. Among them, Aer Therapeutics secured the most recent funding round in August, 2026.

ReViral - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.

Website: reviral.co.uk
Social
Email ID: *****@reviral.co.uk
Registered Address: 2530 Meridian Parkway 2nd Floor Durham North Carolina

Key Metrics

Founded Year

2011

Location

London, United Kingdom

Stage

Acqui-Hired

Total Funding

$176M in 5 rounds

Latest Funding Round

Series C, Aug 25, 2020, $*****

Investors

New Leaf Venture Partners & 7 more

Ranked

15^th among 65 active competitors

Annual Revenue

£1M - £10M as on Apr 30, 2021

Employee Count

5 as on Sep 30, 2026

Similar Companies

Precigen & 84 more

View ReViral's full profile

ReViral is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
REVIRAL INC CIN: 7357943 , United States, Active	Dec 31, 2010	-	27 (As on Dec 31, 2020)	-
Reviral Limited CIN: 7486063 , Germany, Active	Jan 09, 2011	£1M - £10M (As on Apr 30, 2021)	28 (As on Dec 31, 2021)

ReViral has raised a total funding of $176M over 5 rounds. Its first funding round was on Dec 02, 2014. Its latest funding round was a Series C round on Aug 25, 2020 for $*****. 7 investors participated in its latest round. ReViral has 8 institutional investors.

Here is the list of recent funding rounds of ReViral:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 25, 2020	9080481	Series C	8099913	7483081	8155989	7731924
Aug 01, 2018	2478766	Series B	6602349	3222514	9682841	Perceptive Advisors & 3 more
Jul 2018	1880374	Series B	5467897	8308607	New Leaf Venture Partners & 1 more	Perceptive Advisors & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of ReViral's funding rounds and investors

The founders of ReViral are Khattereh Ahmadi and James Lumley.

Here are the details of ReViral's key team members:

Khattereh Ahmadi: Co-Founder of ReViral and founder of 1 other company. They serve on the board of 1 company.
James Lumley: Co-Founder of ReViral.

ReViral's Board of Directors

ReViral's board has 10 active members. Ron Hunt, Lawrence M Blatt, Yi Zhou, Chau Khuong, Iain Dukes, Nanna Lüneborg, Raphaël Wisniewski, Alex Sapir, Richard Ken and Kenneth Palmero are independent board members.

Here is the list of ReViral's board of directors:

Name	Type	Representing	Status	Duration
wyoqxcj	Team	-	Past	7y 9m
painlw{	Team	-	Past	7y 1m
ujhnncj	Team	-	Past	5y 2m
Ron Hunt	Independent board member	-	Current	6y 8m
hwfogaz	Independent board member	-	Current	5y 4m
pwskqbd	Independent board member	-	Current	6y 4m
rhxonxi	Independent board member	-	Current	6y 7m
qaqqyii	Independent board member	-	Current	4y 7m
xmkujpw	Independent board member	-	Current	5y 8m
kqyloqn	Independent board member	-	Current	3y 9m
ldlxuzi	Independent board member	-	Current	4y 5m
hbjtwpc	Independent board member	-	Current	9y 8m
usnyqle	Independent board member	-	Current	8y 4m
untiihd	Independent board member	-	Past	4y 7m
ljltmec	Independent board member	-	Past	7y 1m
qsqfv{l	Independent board member	-	Past	5y 6m
ffbx{rl	Independent board member	-	Past	9y 5m
puwfako	Independent board member	-	Past	7y 8m
rkcwos{	Independent board member	-	Past	1y 1m

View details of ReViral's Founder profiles and Board Members

ReViral's employee count trend

ReViral has 5 employees as of Sep 26. Here is ReViral's employee count trend over the years:

Uncover ReViral's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ReViral include Precigen, Pulmocide and Genome & Company. Here is the list of Top 10 competitors of ReViral, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Precigen 1998, Germantown (United States), Public	Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases	$234M	Checkmate Capital	66/100
2nd	Pulmocide 2013, London (United Kingdom), Series C	Developer of inhaled antifungal medicines for treating respiratory lung infections	$205M	Pictet Group, Vivo Capital & 15 others	56/100
3rd	Genome & Company 2015, Seongnam-si (South Korea), Public	Developer of microbiome-based immuno-oncology drugs	-	IMM Investment, Timefolio Capital & 8 others	55/100
4th	AMILI 2019, Singapore (Singapore), Series A	Provider of gut microbiome data insights, analytics, tests, and therapeutics	$10.5M	Vulcan Capital, East Ventures & 8 others	52/100
5th	Pneumagen 2016, St Andrews (United Kingdom), Series A	Developer of a treatment for viral respiratory tract infections and cancer	$18.3M	Scottish Investment Bank, Esperante & 23 others	51/100
6th	Relief Therapeutics 2013, Geneva (Switzerland), Public	Developer of drugs for treating pulmonary and infectious diseases	$2.75M	NewH2, Swkfunding	49/100
7th	Siolta Therapeutics 2016, San Francisco (United States), Series C	Provider of microbiome therapeutics for treating multiple diseases	$42M	SymBiosis, Seventure Partners & 7 others	43/100
8th	Blue Lake Biotechnology 2019, Athens (United States), Series A	Developer of intranasal vaccines using a parainfluenza virus-based vector	$8.75M	-	42/100
9th	Pulmotect 2007, Houston (United States), Series B	Developer of therapeutics against lung infections	$25.1M	Aquinas Companies, Fannin Innovation Studio ... & 5 others	42/100
10th	Aer Therapeutics 2014, Raleigh (United States), Series A	Developing an inhaled approach to treat lung disease with excess mucus and mucus plugs	$41M	Canaan, Orbimed & 1 others	40/100
15th	ReViral 2011, London (United Kingdom), Acqui-Hired	Developer of antiviral compounds for RSV	$176M	Perceptive Advisors, New Leaf Venture Partners ... & 6 others	35/100